References
- Cancer in South Australia. Incidence, mortality and survival 1977 to 1982. South Australian Health Commission. 1984, South Australian Government Printer ISNN0725–4091
- Langlands A O, Pocock S J, Kerr G R, Gore S M. Long term survival of patients with breast cancer: a study of the curability of the disease. Br Med J 1979; 1247–51
- Roberts J G, Bligh A S, Gravelle I H, et al. Evaluation of radiography and isotopic scintigraphy for detecting skeletal metastases in breast cancer. Lancet 1976; 1: 237–9
- Fisher E R, Redmond C, Fisher B. Histological grading of breast cancer. Pathol Annu 1980; 15: 239–51
- Weiss M A, Michael J G, Pesce A J, Di Persio L. Heterogeneity of B2 microglobulin in human breast carcinoma. Lab Invest 1981; 45: 46–57
- Fisher B, Carbone P, Economou S G, et al. Phenylalanine mustard (LPAM) in the management of primary breast cancer. A report of early findings. N Engl J Med 1975; 292: 117–22
- Neville A M, Cooper E H. Biochemical monitoring of cancer. Ann Clin Biochem 1976; 13: 283–305
- Coombes R C, Powles T J, Gazet J C, et al. A biochemical approach to the staging of human breast cancer. Cancer 1977; 40: 937–44
- Coombes R C, Gazet J C, Sloane J P, et al. Biochemical markers in human breast cancer. Lancet 1977; 1: 132–4
- Shuster J, Gold P, Poulik M D. β2-microglobulin levels in cancerous and other disease states. Clin Chim Acta 1976; 67: 307–13
- Norfolk D R, Child J A, Cooper E H, et al. Serum β2-microglobulin in myelomatosis: potential value in stratification and monitoring. Br J Cancer 1980; 42: 510–5
- Papaioannou D, Geggie P, Klassen J. Study of serum β2-microglobulin levels in breast cancer patients. Clin Chim Acta 1979; 99: 37–41
- Teasdale C, Mander R, Fifield R, et al. Serum β2-microglobulin in controls and cancer patients. Clin Chim Acta 1977; 78: 135–43
- Adami H O, Hallgren R, Lundquist G. Serum β2 microglobulin in women with breast cancer and in age-matched, non-hospitalised controls. Clin Chem Acta 1979; 93: 43–9
- Hayward J L, Rubens R D, Carbone P P, et al. Assessment of response to therapy in advanced breast cancer. Br J Cancer 1977; 35: 292–7
- Coombes R C, Easty G C, Detre S I, et al. Secretion of immuno reactive celutonin by human breast carcinomes. Br Med J 1975; 197–9
- Tormey D C, Waalkes T P, Ahmenn D, et al. Biological markers in breast carcinoma. Incidence of abnormalities of CEA, HC9, three polyamines and three minor nucleosides. Cancer 1975; 35: 1095–2000
- Home C HW, Reid I N, Milne G D. Prognostic significance of inappropriate production of pregnancy proteins by breast cancers. Lancet 1976; 2: 279–83
- Itillyard J W, Keyser K W, Newcombe R G, et al. Biochemical aids to the staging of breast cancer. Clin Biochem 1982; 15: 9–12
- Borthwick N M, Wilson D W, Bell P A. Carcinoembryonic antigen (CEA) in patients with breast cancer. Eur J Cancer 1977; 13: 171–6